Chison Medical Technologies Co., Ltd. (688358.SS)
CNY 28.77
(1.02%)
CNY 28.77
(1.02%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 157.82 Million CNY | 27.29% |
| 2022 | 125.83 Million CNY | 20.15% |
| 2021 | 132 Million CNY | -10.42% |
| 2020 | 120.21 Million CNY | -6.22% |
| 2019 | 125.25 Million CNY | 10.83% |
| 2018 | 113.58 Million CNY | 37.49% |
| 2017 | 79.31 Million CNY | 167.21% |
| 2016 | 38.56 Million CNY | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q3 | 30.63 Million CNY | 24.01% |
| 2024 Q1 | 54.23 Million CNY | 429.01% |
| 2024 Q2 | 23.4 Million CNY | -56.12% |
| 2023 Q2 | 65.03 Million CNY | 3.01% |
| 2023 FY | - CNY | 27.29% |
| 2023 Q4 | -17.11 Million CNY | -144.98% |
| 2023 Q1 | 63.13 Million CNY | 277.31% |
| 2023 Q3 | 38.04 Million CNY | -41.5% |
| 2022 Q1 | 25.39 Million CNY | 139.2% |
| 2022 Q4 | -35.6 Million CNY | -158.36% |
| 2022 Q2 | 64.51 Million CNY | 154.05% |
| 2022 FY | - CNY | 20.15% |
| 2022 Q3 | 61 Million CNY | -5.44% |
| 2021 FY | - CNY | -10.42% |
| 2021 Q4 | 10.61 Million CNY | -65.62% |
| 2021 Q3 | 30.87 Million CNY | -13.07% |
| 2021 Q1 | 19.91 Million CNY | -64.7% |
| 2021 Q2 | 35.52 Million CNY | 78.39% |
| 2020 FY | - CNY | -6.22% |
| 2020 Q3 | 29.57 Million CNY | -10.33% |
| 2020 Q2 | 32.98 Million CNY | 178.7% |
| 2020 Q1 | 11.83 Million CNY | -77.89% |
| 2020 Q4 | 56.41 Million CNY | 90.74% |
| 2019 FY | - CNY | 10.83% |
| 2019 Q4 | 53.51 Million CNY | 119.62% |
| 2019 Q3 | 24.36 Million CNY | -35.04% |
| 2019 Q2 | 37.51 Million CNY | 327.65% |
| 2019 Q1 | 8.77 Million CNY | -81.8% |
| 2018 FY | - CNY | 37.49% |
| 2018 Q4 | 48.19 Million CNY | 0.0% |
| 2017 FY | - CNY | 167.21% |
| 2016 FY | - CNY | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Shenzhen Lifotronic Technology Co., Ltd. | 375.48 Million CNY | 57.968% |